26例晚期胃癌维持化疗的临床治疗体会

Clinical efficacy and study of maintenance therapy for advanced gastric cancer

目的:探讨晚期胃癌一线化疗后继续维持化疗的有效性与安全性。方法:26例初治晚期胃癌患者采用一线方案化疗6~8周期,疗效评价达疾病控制后,维持化疗持续到疾病进展或出现不能耐受毒副反应为止。结果:26例可评价疗效患者,完全缓解2例,部分缓解7例,疾病稳定9例,疾病进展8例。治疗的总有效率为34.6%,疾病控制率为69.2%,患者的中位无进展生存时间(PFS)为9.7个月,中位OS为17.9个月;维持化疗毒副反应轻微,无治疗相关性死亡。结论:维持化疗方案治疗晚期胃癌可延长患者无进展生存期和总生存期,且毒副反应安全耐受。

Objective:To discuss the clinical efficacy,clinical benefit rate and adverse reaction of maintenance therapy for advanced gastric cancer.Methods:Selected 26 cases with advanced gastric cancer underwent chemotherapy for 6-8 cycles with clinical efficacy of PR or SD were received Maintenance therapy.And Maintenance chemotherapy continued until disease progression or intolerance of adverse effects.The control group receive maintenance therapy group was 34.6%,DCR(CR+PR+SD)was 69.2%.No disease progression time of the maintenance therapy were 9.7 months which showed maintenance therapy group were 17.9 months Adverse reactions of the maintenance therapy were slight and no treatment-related deaths occurred.Conclusion:maintenance therapy for advanced gastric cancer delay disease progression and increase overall survival time,with tolerable adverse reactions.